Literature DB >> 9989794

Identification of novel and known mutations in the genes for keratin 5 and 14 in Danish patients with epidermolysis bullosa simplex: correlation between genotype and phenotype.

C B Sørensen1, A S Ladekjaer-Mikkelsen, B S Andresen, F Brandrup, N K Veien, S K Buus, I Anton-Lamprecht, T A Kruse, P K Jensen, H Eiberg, L Bolund, N Gregersen.   

Abstract

Epidermolysis bullosa simplex (EBS) is a group of autosomal dominant inherited skin diseases caused by mutations in either the keratin 5 (K5) or the keratin 14 (K14) genes and characterized by development of intraepidermal skin blisters. The three major subtypes of EBS are Weber-Cockayne, Koebner, and Dowling-Meara, of which the Dowling-Meara form is the most severe. We have investigated five large Danish families with EBS and two sporadic patients with the Dowling-Meara form of EBS. In the sporadic Dowling-Meara EBS patients, a novel K14 mutation (N123S) and a previously published K5 mutation (N176S) were identified, respectively. A novel K14 mutation (K116N) was found in three seemingly unrelated families, whereas another family harbored a different novel K14 mutation (L143P). The last family harbored a novel K5 mutation (L325P). The identified mutations were not present in more than 100 normal chromosomes. Six polymorphisms were identified in the K14 gene and their frequencies were determined in normal controls. These polymorphisms were used to show that the K14 K116N mutation was located in chromosomes with the same haplotype in all three families, suggesting a common ancestor. We observed a strict genotype-phenotype correlation in the investigated patients as the same mutation always resulted in a similar phenotype in all individuals with the mutation, but our results also show that it is not possible to predict the EBS phenotype merely by the location (i.e., head, rod, or linker domains) of a mutation. The nature of the amino acid substitution must also be taken into account.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989794     DOI: 10.1046/j.1523-1747.1999.00495.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

Review 1.  Protein misfolding, aggregation, and degradation in disease.

Authors:  Niels Gregersen; Lars Bolund; Peter Bross
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

2.  Morphologic and molecular characterization of two novel Krt71 (Krt2-6g) mutations: Krt71rco12 and Krt71rco13.

Authors:  Fabian Runkel; Matthias Klaften; Kerstin Koch; Volker Böhnert; Heinrich Büssow; Helmut Fuchs; Thomas Franz; Martin Hrabé de Angelis
Journal:  Mamm Genome       Date:  2006-12-01       Impact factor: 3.224

3.  The mechanical behavior of mutant K14-R125P keratin bundles and networks in NEB-1 keratinocytes.

Authors:  Daniel R Beriault; Oualid Haddad; John V McCuaig; Zachary J Robinson; David Russell; E Birgitte Lane; Douglas S Fudge
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

4.  Exome sequencing reveals a novel mutation, p.L325H, in the KRT5 gene associated with autosomal dominant Epidermolysis Bullosa Simplex Koebner type in a large family from western India.

Authors:  Shamsudheen K Vellarikkal; Ashok Patowary; Meghna Singh; Renu Kumari; Mohammed Faruq; Dilip C Master; Sridhar Sivasubbu; Vinod Scaria
Journal:  Hum Genome Var       Date:  2014-09-04

5.  Novel sporadic and recurrent mutations in KRT5 and KRT14 genes in Polish epidermolysis bullosa simplex patients: further insights into epidemiology and genotype-phenotype correlation.

Authors:  K Wertheim-Tysarowska; M Ołdak; A Giza; A Kutkowska-Kaźmierczak; J Sota; D Przybylska; K Woźniak; D Śniegórska; K Niepokój; A Sobczyńska-Tomaszewska; A M Rygiel; R Płoski; J Bal; C Kowalewski
Journal:  J Appl Genet       Date:  2015-10-02       Impact factor: 3.240

6.  Traceless Targeting and Isolation of Gene-Edited Immortalized Keratinocytes from Epidermolysis Bullosa Simplex Patients.

Authors:  Magomet Aushev; Ulrich Koller; Claudio Mussolino; Toni Cathomen; Julia Reichelt
Journal:  Mol Ther Methods Clin Dev       Date:  2017-07-05       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.